Back to top
more

Replimune Group (REPL)

(Delayed Data from NSDQ)

$5.22 USD

5.22
514,122

-0.44 (-7.77%)

Updated May 24, 2024 04:00 PM ET

After-Market: $5.23 +0.01 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for REPL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Replimune Group, Inc. [REPL]

Reports for Purchase

Showing records 161 - 180 ( 191 total )

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 161

11/10/2019

Company Report

Pages: 9

RP1 Ph 1 Dataset Impressive; Melanoma Program Expanded; Raising PT to $30

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 162

11/10/2019

Company Report

Pages: 9

SITC Update Is the Tip of the Iceberg

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 163

11/08/2019

Company Report

Pages: 10

SITC - Early Data Infectious as Some Tumors Melt

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 164

11/08/2019

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 165

11/01/2019

Daily Note

Pages: 13

Biotechnology - SITC 2019 Abstract Title Preview for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 50.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 166

10/25/2019

Company Report

Pages: 4

RP2 Phase 1/2 Trial Initiates Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 167

10/16/2019

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 168

10/16/2019

Daily Note

Pages: 8

Positive Early Data in CSCC; Ph 2 Study Initiates

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 169

10/16/2019

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 170

10/16/2019

Company Report

Pages: 4

Initial CSCC data hint that RP1 may be more potent than T-VEC.- Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 171

10/15/2019

Company Report

Pages: 10

RP1''s Addition to Anti-PD-1 mAbs For Anticancer Therapy Is Justified

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 172

10/04/2019

Industry Report

Pages: 3

SITC Is Only 33 Days Away: Abstract Titles Released

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 173

10/03/2019

Industry Report

Pages: 30

Biotechnology - ESMO 2019 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 75.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 174

09/30/2019

Company Report

Pages: 6

Subsequent Therapy Imbalances Obviate T-VEC + Yervoy ESMO Data Extrapolations; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 175

09/04/2019

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 176

09/04/2019

Company Report

Pages: 23

Will GALV plus GM-CSF Be a Game- Changer? Initiating at Buy, $20 PT

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 75.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 177

08/30/2019

Daily Note

Pages: 10

HEALTHCARE- The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 178

08/19/2019

Company Report

Pages: 7

Fiscal Q1 Financials; First Look at RP1 Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 179

08/19/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Replimune Group, Inc.

Industry: Medical - Biomedical and Genetics

Record: 180

08/15/2019

Company Report

Pages: 4

1Q20 Financials Reported; Programs Advancing on Track; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party